Trials / Completed
CompletedNCT00116779
A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer
An Open-label, Randomized, Multi-center, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer Dosed for Thirteen 28-day Cycles
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 127 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study was to contribute, along with other such dose-finding studies, to the identification of the most effective treatment regimen for a one month depot injection of degarelix in the treatment of prostate cancer by a rapid and sustained suppression of testosterone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Degarelix | Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles. |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2005-08-01
- Completion
- 2005-08-01
- First posted
- 2005-07-01
- Last updated
- 2011-12-19
- Results posted
- 2009-03-20
Locations
35 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00116779. Inclusion in this directory is not an endorsement.